Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467984 | 1.00 | UGCG (0.36) | UGCGCTSLCTSSCTSKCTSC | |
| SCHEMBL26388488 | 0.90 | CTSL (0.42) | UGCGCTSLCTSSCTSKCTSC | |
| SCHEMBL26390199 | 0.90 | CTSL (0.42) | UGCGCTSLCTSSCTSKCTSC | |
| SCHEMBL26388396 | 0.90 | CETP (0.36) | UGCGABL1CETPKCNH2SSTR4 | |
| SCHEMBL30468007 | 0.90 | CETP (0.36) | UGCGABL1CETPKCNH2SSTR4 | |
| SCHEMBL30467952 | 0.88 | DGAT2 (0.38) | UGCGCTSLCTSSCTSKCTSC | |
| SCHEMBL30468000 | 0.88 | DGAT2 (0.38) | UGCGCTSLCTSSCTSKCTSC | |
| SCHEMBL30467992 | 0.88 | GPR119 (0.37) | UGCGABL1SSTR4SSTR1 | |
| SCHEMBL25675643 | 0.83 | SMYD3 (0.39) | UGCGCTSLCTSSCTSKCTSC | |
| Trifluoroacetic Acid SCHEMBL30468043 | 0.82 | SSTR4 (0.36) | UGCGABL1CETPKCNH2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | claimed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | UGCG 3329/4885CTSL 943/4885CTSS 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.